Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT06982690
What this trial is testing

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

Who this might be right for
NMIBCTURBTBladder (Urothelial, Transitional Cell) Cancer+3 more
National Taiwan University Hospital 370
Large-scale testing (Phase 3)Active Not RecruitingNCT05943106
What this trial is testing

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Who this might be right for
Non-Muscle- Invasive Bladder Cancer
AstraZeneca 100
Not applicableLooking for participantsNCT05123625
What this trial is testing

Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC

Who this might be right for
Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University 200
Early research (Phase 1)Study completedNCT02808143
What this trial is testing

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial Carcinoma+1 more
Northwestern University 9
Testing effectiveness (Phase 2)UnknownNCT04730232
What this trial is testing

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
High-RiskNon-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT03317158
What this trial is testing

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial CarcinomaBladder Cancer
Noah Hahn, M.D. 186
Not applicableUnknownNCT05276167
What this trial is testing

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Who this might be right for
High-Risk, Non-Muscle Invasive Bladder Urothelial CarcinomaPerfusion; ComplicationsIntraoperative Complications
Henan Cancer Hospital 40
Testing effectiveness (Phase 2)Study completedNCT04496219
What this trial is testing

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Urothelial Carcinoma In SituRecurrent Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+3 more
Fred Hutchinson Cancer Center 45
Testing effectiveness (Phase 2)Looking for participantsNCT05410730
What this trial is testing

SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

Who this might be right for
High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd. 150
Early research (Phase 1)Active Not RecruitingNCT06181266
What this trial is testing

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Who this might be right for
NMIBCHigh Risk NMIBCNon Muscle Invasive Bladder Cancer
Prokarium Ltd 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07064863
What this trial is testing

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

Who this might be right for
NMIBCNon-Muscle Invasive Bladder Urothelial CarcinomaBladder (Urothelial, Transitional Cell) Cancer+1 more
Queen's University 31
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Large-scale testing (Phase 3)Study completedNCT00406068
What this trial is testing

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Neoplasms
Bioniche Life Sciences Inc. 129
Large-scale testing (Phase 3)Looking for participantsNCT06696794
What this trial is testing

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang 180
Large-scale testing (Phase 3)Active Not RecruitingNCT03091660
What this trial is testing

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Who this might be right for
Stage 0 Bladder Urothelial CarcinomaStage 0is Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma
SWOG Cancer Research Network 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06567743
What this trial is testing

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Who this might be right for
High-Risk Non-Muscle-Invasive Bladder Cancer
CG Oncology, Inc. 325
Testing effectiveness (Phase 2)Looking for participantsNCT06971614
What this trial is testing

T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Who this might be right for
Nonmuscle-invasive Bladder Cancer
ImmVira Pharma Co. Ltd 160
Large-scale testing (Phase 3)Looking for participantsNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Next Page